Erratum in "The reasons for prescribing antitumor drugs beyond the registered indications in real clinical practice: a retrospective study"(DOI: 10.26442/18151434.2024.4.203108)

In the article «The reasons for prescribing antitumor drugs beyond the registered indications in real clinical practice: A retrospective study», published in the Journal of Modern Oncology, Vol. 26, No.4, 2024 (DOI: 10.26442/18151434.2024.4.203108), errors were made: The number of used medicinal products (MPs) was corrected in the sentence "The use of 47 MPs was reported, including 46 antitumor agents and drugs with antitumor activity as part of 73 antitumor drug therapy regimens". Correct wording of the sentence: "The use of 46 MPs as part of 73 antitumor drug therapy regimens was reported". The names of 3 drugs and 1 applied regimen in 4 rows of the table have been corrected. Table row: The correct version: 36 Palbociclib + fulvestrant Palbociclib 36 Palbociclib + fulvestrant Cyclophosphamide Table row: The correct version: 46 Docetaxel + carboplatin + trastuzumab Cyclophosphamide 46 Docetaxel + carboplatin + trastuzumab Calcium folinate Table row: The correct version: 47 Capecitabine + bevacizumab Calcium folinate 47 Capecitabine + bevacizumab – Table row: The correct version: 70 FOLFIRINOX + bevacizumab (oxaliplatin, irinotecan,calcium folinate, fluorouracil, bevacizumab) – 70 FOLFOXIRI + bevacizumab (oxaliplatin, irinotecan,calcium folinate, fluorouracil, bevacizumab) – The errors were corrected at the request of the authors' team. The publisher replaced the original version of the published article with the corrected one; the information on the website was also corrected. The publisher apologizes to readers and authors for the errors and is confident that the correction of errors will ensure the correct perception and interpretation of the results of the study described in the text.